Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: Emphasis on ponatinib
Anand Singh, Prachi Umbarkar, Sultan Tousif, et al.
International Journal of Cardiology (2020) Vol. 316, pp. 214-221
Open Access | Times Cited: 51

Showing 1-25 of 51 citing articles:

Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection
Marco Bruno Morelli, Chiara Bongiovanni, Silvia Da Pra, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 94
Integrated Stress Response Potentiates Ponatinib-Induced Cardiotoxicity
Gege Yan, Zhenbo Han, Youjeong Kwon, et al.
Circulation Research (2024) Vol. 134, Iss. 5, pp. 482-501
Closed Access | Times Cited: 11
Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option
Jeffrey H. Lipton, Tim H. Brümmendorf, Carlo Gambacorti‐Passerini, et al.
Blood Reviews (2022) Vol. 56, pp. 100968-100968
Open Access | Times Cited: 35
Molecules and Mechanisms to Overcome Oxidative Stress Inducing Cardiovascular Disease in Cancer Patients
Francesco Sabbatino, Valeria Conti, Luigi Liguori, et al.
Life (2021) Vol. 11, Iss. 2, pp. 105-105
Open Access | Times Cited: 39
Interaction of a Third‐Generation Tyrosine Kinase Inhibitor with dsDNA: Electrochemical and Spectroscopic Studies
Kamila Koszelska, M. Wypych, Mateusz Kciuk, et al.
Electroanalysis (2025) Vol. 37, Iss. 2
Closed Access
Cancer Therapy-Induced Cardiotoxicity—A Metabolic Perspective on Pathogenesis, Diagnosis and Therapy
Anurag Choksey, Kerstin N. Timm
International Journal of Molecular Sciences (2021) Vol. 23, Iss. 1, pp. 441-441
Open Access | Times Cited: 32
Immuno-inflammatory mechanisms in cardio-oncology: new hopes for immunotargeted therapies
Meiqi Miao, Xinxin Liu, Han Zhang, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Cardiotoxicity of Novel Targeted Hematological Therapies
Valentina Giudice, Carmine Vecchione, Carmine Selleri
Life (2020) Vol. 10, Iss. 12, pp. 344-344
Open Access | Times Cited: 30
Tyrosine Kinase Inhibitors-Induced Arrhythmias: From Molecular Mechanisms, Pharmacokinetics to Therapeutic Strategies
Mengfei Cheng, Fang Yang, Jiahui Liu, et al.
Frontiers in Cardiovascular Medicine (2021) Vol. 8
Open Access | Times Cited: 24
Sodium-glucose cotransporter type 2 inhibitors prevent ponatinib-induced endothelial senescence and disfunction: A potential rescue strategy
Rosalinda Madonna, Serena Barachini, Stefania Moscato, et al.
Vascular Pharmacology (2021) Vol. 142, pp. 106949-106949
Closed Access | Times Cited: 23
Pharmacogenomics in drug-induced cardiotoxicity: Current status and the future
Moyun Li, Peng Li-ming, Xiaoping Chen
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 17
Molecular Imaging Biomarkers in Cardiooncology: A View on Established Technologies and Future Perspectives
David Kersting, Ilektra-Antonia Mavroeidi, Stephan Settelmeier, et al.
Journal of Nuclear Medicine (2023) Vol. 64, Iss. Supplement 2, pp. 29S-38S
Open Access | Times Cited: 10
RIPK2 inhibitors for disease therapy: Current status and perspectives
Erkang Tian, Changhan Zhou, Shuqi Quan, et al.
European Journal of Medicinal Chemistry (2023) Vol. 259, pp. 115683-115683
Closed Access | Times Cited: 9
Reengineering Ponatinib to Minimize Cardiovascular Toxicity
Anna P. Hnatiuk, Arne A.N. Bruyneel, Dhanir Tailor, et al.
Cancer Research (2022) Vol. 82, Iss. 15, pp. 2777-2791
Open Access | Times Cited: 14
Recent Perspectives on Cardiovascular Toxicity Associated with Colorectal Cancer Drug Therapy
Monu Kumar Kashyap, Shubhada Mangrulkar, Sapana Kushwaha, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 10, pp. 1441-1441
Open Access | Times Cited: 7
Sex‐related differential susceptibility to ponatinib cardiotoxicity and differential modulation of the Notch1 signalling pathway in a murine model
Rosalinda Madonna, Damiana Pieragostino, Maria Concetta Cufaro, et al.
Journal of Cellular and Molecular Medicine (2022) Vol. 26, Iss. 5, pp. 1380-1391
Open Access | Times Cited: 12
Designing Novel BCR-ABL Inhibitors for Chronic Myeloid Leukemia with Improved Cardiac Safety
Mallesh Pandrala, Arne A.N. Bruyneel, Anna P. Hnatiuk, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 16, pp. 10898-10919
Open Access | Times Cited: 11
Connexin 43 and Connexin 26 Involvement in the Ponatinib-Induced Cardiomyopathy: Sex-Related Differences in a Murine Model
Rosalinda Madonna, Stefania Moscato, E. Polizzi, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 11, pp. 5815-5815
Open Access | Times Cited: 13
Metabolic activation of tyrosine kinase inhibitors: recent advance and further clinical practice
Miao Yan, Wenqun Li, Wenbo Li, et al.
Drug Metabolism Reviews (2022) Vol. 55, Iss. 1-2, pp. 94-106
Closed Access | Times Cited: 9
PTEN‐AKT pathway attenuates apoptosis and adverse remodeling in ponatinib‐induced skeletal muscle toxicity following BMP‐7 treatment
Ayushi Srivastava, Dinender K. Singla
Physiological Reports (2023) Vol. 11, Iss. 6
Open Access | Times Cited: 5
Mitochondrial Dysfunction in Cardiotoxicity Induced by BCR-ABL1 Tyrosine Kinase Inhibitors -Underlying Mechanisms, Detection, Potential Therapies
Sheng Sun, Jiqiu Qin, Wenhao Liao, et al.
Cardiovascular Toxicology (2023) Vol. 23, Iss. 7-8, pp. 233-254
Closed Access | Times Cited: 5
Depletion of lncRNA MEG3 Ameliorates Imatinib-Induced Injury of Cardiomyocytes via Regulating miR-129-5p/HMGB1 Axis
Peng Tang, Jinjian Zhou, Huagang Liu, et al.
Analytical Cellular Pathology (2023) Vol. 2023, Iss. 1
Open Access | Times Cited: 4
The intersection of heart failure and cancer in women: a review
Sara Tyebally, Ching‐Hui Sia, Daniel H. Chen, et al.
Frontiers in Cardiovascular Medicine (2024) Vol. 11
Open Access | Times Cited: 1
Applied Cardio-Oncology in Hematological Malignancies: A Narrative Review
Evdokia Mandala, Kyranna Lafara, Dimitrios Kokkinovasilis, et al.
Life (2024) Vol. 14, Iss. 4, pp. 524-524
Open Access | Times Cited: 1
The Role of Pharmacogenomics in Drug-Induced Cardiovascular Toxicity
Ranko Škrbić, Milica Gajić Bojić, Miloš P. Stojiljković
Advances in biochemistry in health and disease (2024), pp. 453-476
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top